AMLX catalyst calendar

Amylyx Pharmaceuticals, Inc.

Upcoming catalysts
2
Cash runway
20.4 months
Cash & investments
$251M
Phase 3 programs
4

Amylyx Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 20.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 5, 2026 est. Next quarterly earnings (projected) Earnings —
February 15, 2027 AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis Trial Milestone Phase 1

Track AMLX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open AMLX in the tracker

Recent history

DateEventTypePhase
September 8, 2026 8-K filed: Material agreement Corporate —
August 20, 2026 8-K filed: Material agreement Corporate —
August 18, 2026 8-K filed: Reg FD disclosure, Other event Filing —
August 18, 2026 8-K filed: Other event Filing —
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 8, 2026 Avexitide for Treatment of Post-Bariatric Hypoglycemia Trial Milestone Phase 3
May 7, 2026 Quarterly results filed (8-K) Earnings —
March 24, 2026 8-K filed: Reg FD disclosure Filing —
March 3, 2026 Quarterly results filed (8-K) Earnings —
January 8, 2026 8-K filed: Reg FD disclosure, Other event Filing —
November 6, 2025 Quarterly results filed (8-K) Earnings —
September 30, 2025 AMX0035 and Progressive Supranuclear Palsy Trial Milestone Phase 2/Phase 3
September 10, 2025 8-K filed: Material agreement Corporate —
August 27, 2025 8-K filed: Other event Filing —
August 7, 2025 Quarterly results filed (8-K) Earnings —
May 8, 2025 Quarterly results filed (8-K) Earnings —
October 16, 2024 Extension Study Evaluating The Safety And Tolerability of AMX0035 Trial Milestone Phase 3
July 23, 2024 AMX0035 in Adult Patients With Wolfram Syndrome Trial Milestone Phase 2
December 30, 2022 A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS) Trial Milestone Phase 2/Phase 3
March 1, 2021 Open Label Extension Study of AMX0035 in Patients With ALS Trial Milestone Phase 2
October 22, 2020 Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease Trial Milestone Phase 2
September 25, 2019 AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.